Kodiak Sciences(NASDAQ) KOD

Kodiak Sciences Inc. makes medicines for people with serious eye conditions. These treatments help prevent blindness and vision loss. The company's drugs are designed to stay in the eye longer to reduce treatment frequency.

Retina Treatment Pipeline

• Zenkuda (tarcocimab): Lead drug candidate for retinal vascular diseases; completed four successful Phase 3 studies in diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration.
• KSI-501: Bispecific therapy built on the company's platform; targets two different disease pathways to improve results for patients with wet age-related macular degeneration.
• KSI-101: High-strength therapy for patients with macular edema secondary to inflammation; currently in Phase 3 trials to address a market segment separate from standard treatments.
• ABC Platform: Molecular engineering technology merging protein-based and chemistry-based therapies; creates long-lasting medicines for the eye.

Recent Clinical Progress

• Completed enrollment in the Phase 3 DAYBREAK study for Zenkuda and KSI-501 in wet age-related macular degeneration.
• Initiated the Phase 3 ALTO study of KSI-501 in August 2026 for patients with diabetic macular edema.
• Established a custom-designed drug manufacturing facility in partnership with Lonza to support future commercial production.
• Advanced the VETi platform, which uses artificial intelligence and a wearable headset for retina care and cognitive sciences.

Science of Durability

Kodiak uses its Antibody Biopolymer Conjugate platform to create retinal medicines that remain active for longer periods than existing therapies. The company also develops digital health technology like wearable headsets to improve how eye diseases are managed.

The Numbers Behind Science

• Net loss was $123.8 million for the six months ended June 30, 2026, compared to $111.8 million for the same period in 2025.
• Research and development expenses rose to $104.6 million for the six months ended June 30, 2026.
• Cash and cash equivalents totaled $125.9 million as of June 30, 2026.
• Accumulated deficit reached $1.7 billion as of June 30, 2026, leading to substantial doubt about the company's ability to continue as a going concern.
• Market capitalization was approximately $2.5 billion as of the second quarter of 2026.

The Evolving Mission

Kodiak has transitioned from an early research firm into a late-stage clinical developer with multiple candidates nearing regulatory submission. Its growth centers on advancing a diverse pipeline of multi-specific therapies and integrating vision-focused digital technologies.